photo The Reaads IgA anti-phosphatidylserine (aPS) ELISA test kit has been cleared for in vitro diagnostic use by the FDA.
     This semi-quantitative assay for the detection of aPS antibodies in human serum aids in assessing the risk of thrombosis in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (antiphospholipid Syndrome). This company offers a line of assays for the evaluation of antiphospholipid antibodies including aPS, anticardiolipin and anti-B2GPI (IgG, IgM, and IgA).
     The assay requires three room temperature incubations (15, 15, and 10 min.), with results available in less than an hour. A single-point calibration calculates patient results for maximum cost efficiency and precision as demonstrated with the other Reaads antiphospholipid assays.
     Clinical trials resulted in 95 percent specificity with a healthy blood donor population. Good clinical correlation was seen when both primary and secondary antiphospholipid syndrome patients samples were tested.
Keyword: test kit, reagent, ELISA